Retrospective, observation study: Quantitative and qualitative effect of ezetimibe and HMG-CoA reductase inhibitors on LDL-cholesterol: Are there disappearance thresholds for small, dense LDL and IDL?

Recent Patents on Cardiovascular Drug Discovery

Volumn 5, Issue 2, 2010, Pages 143-152

  Inoue, Ikuo ^a   Awata, Takuya ^a   Katayama, Shigehiro ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Cholesterol absorption inhibitor; Dense LDL; Hmg coa reductase inhibitor; LDL cholesterol; Mid band lipoprotein cholesterol Ezetimibe; Small

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; EZETIMIBE; FLUINDOSTATIN; FUROSEMIDE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; AZETIDINE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; DYSLIPIDEMIA; FEMALE; HUMAN; KIDNEY FUNCTION TEST; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; HYPERCHOLESTEROLEMIA; MIDDLE AGED;

AGED; AZETIDINES; CHOLESTEROL, LDL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, IDL; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 77953780073     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489010791515386     Document Type: Article

References (32)

1. NCHS. National Health and Nutrition Examination Survey. Health United States 2004; 173.
2. Ministry of Health, Labour and Welfare. The Fifth Cardiovascular Diseases Survey 2000 (in Japanese).
3. Ministry of Health, Labour and Welfare. The National Health and Nutrition Survey 2008 (in Japanese).
4. USDA. Continuing Survey of Food Intakes by Individuals (CSFII). 1998; 1994-6.
5. National Institute of Health and Nutrition. The National Nutrition Survey 2000; 30 (in Japanese).
6. Sudhop T, Lütjohann D, Kodal A, Igel M, Tribble DL, Shah S, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002; 106: 1943-8.
7. Davis HR, Veltri EP. Zetia: Inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J Atheroscler Thromb 2007; 14: 99-108.
8. Bachorik PS, Ross JW. National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: Executive summary. Clin Chem 1995; 41: 1414-20.
9. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
10. Nakano T, Inoue I, Seo M, Takahashi S, Awata T, Komoda T, et al. Rapid and simple profiling of lipoproteins by polyacrylamide-gel disc electrophoresis to determine the heterogeneity of low-density lipoproteins (LDLs) including small, dense LDL. Recent Pat Cardiovasc Drug Discov 2009; 4: 31-6.
11. Kostapanos MS, Milionis HJ, Lagos KG, Rizos CB, Tselepis AD, Elisaf MS. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia. Eur J Pharmacol 2008; 590: 327-32.
12. Yoshino G, Hirano T, Kazumi T. Treatment of small, dense LDL. J Atheroscler Thromb 2002; 9: 266-75.
13. Hirano T, Ito Y, Yoshino G. Measurement of small, dense low-density lipoprotein particles. J Atheroscler Thromb 2005; 12: 67-72.
14. Davidson MH, Ballantyne CM, Kerzner B, Melani L, Sager PT, Lipka L, et al. Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with statins: Randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract 2004; 58: 746-55.
15. Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB. Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: A randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004; 79: 620-9.
16. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, et al.; Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Circulation 2003; 107: 2409-15.
17. Stein EA, Ballantyne CM, Windler E, Sirnes PA, Sussekov A, Yigit Z, et al. Efficacy and tolerability of fluvastatin XL 80mg alone, ezetimibe alone, and the combination of fluvastatin XL 80mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol 2008; 101: 490-6.
18. Catapano AL, Davidson MH, Ballantyne CM, Brady WE, Gazzara RA, Tomassini JE, et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholestero-lemic patients. Curr Med Res Opin 2006; 22: 2041-53.
19. Gordon DJ, Rifkind BM. High-density lipoprotein - the clinical implications of recent studies. N Engl J Med 1989; 321:1311-6.
20. Cheung RC, Morrell JM, Kallend D, Watkins C, Schuster H. Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study. Int J Cardiol 2005; 100: 309-16.
21. Crouse JR III, Frohlich J, Ose L, Mercuri M, Tobert JA. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Am J Cardiol 1999; 83: 1476-7.
22. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998; 97: 1453-60.
23. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.
24. Zheng S, Hoos L, Cook J, Tetzloff G, Davis H Jr, van Heek M, et al. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur J Pharmacol 2008; 584: 118-24.
25. Sagar PT, Capece R, Lipka L, Strony J, Yang B, Suresh R, et al. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis 2005; 179: 361-7.
26. Bulut D, Hanefeld C, Bulut-Streich N, Graf C, Mügge A, Spiecker M. Endothelial function in the forearm circulation of patients with the metabolic syndrome - effect of different lipid-lowering regimens. Cardiology 2005; 104: 176-80.
27. Nakano, T., Niimi, M., Ogihara, F. Method of measuring cholesterol in remnant-like lipoproteins. WO2006057377 (2006).
28. Tanaka, T. Separating method of lipoprotein using cellulose acetate film. JP2007248131 (2007).
29. Okazaki, M. Method for analyzing lipoproteins. WO2006057440 (2006).
30. Matsuda, T., Wakayama, T. The quantitation method of density using image analysis. JP2004258014 (2004).
31. Matsuda, T., Kubota, A. The method of examination of lipoprotein. JP2005121619 (2005).
32. Matsuda, T., Wakayama, T. Quantitative analysis of densitometric pattern based on genetic algorithm. JP2009299317 (2009).